Prahlad T. Ram
YOU?
Author Swipe
View article: Supplementary Data from Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models
Supplementary Data from Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models Open
Revised Supplementary Data Demonstrating All Supplementary Figures 1-6 and Supplementary Table 1
View article: Data from Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models
Data from Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models Open
CRM1 inhibitors have demonstrated antitumor effects in ovarian and other cancers; however, rational combinations are largely unexplored. We performed a high-throughput drug library screen to identify drugs that might combine well with seli…
View article: Data from GnRH-R–Targeted Lytic Peptide Sensitizes <i>BRCA</i> Wild-type Ovarian Cancer to PARP Inhibition
Data from GnRH-R–Targeted Lytic Peptide Sensitizes <i>BRCA</i> Wild-type Ovarian Cancer to PARP Inhibition Open
EP-100 is a synthetic lytic peptide that specifically targets the gonadotropin-releasing hormone receptor on cancer cells. To extend the utility of EP-100, we aimed to identify effective combination therapies with EP-100 for ovarian cancer…
View article: Data from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4
Data from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4 Open
Systematic approaches for accurate repurposing of targeted therapies are needed. We developed and aimed to biologically validate our therapy predicting tool (TPT) for the repurposing of targeted therapies for specific tumor types by testin…
View article: Supplementary Table 5 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4
Supplementary Table 5 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4 Open
Raw RPPA data for OVCAR 5.
View article: Supplementary Table 4 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4
Supplementary Table 4 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4 Open
Raw RPPA data for OVCAR 4.
View article: Supplementary Data from Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models
Supplementary Data from Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models Open
Revised Supplementary Data Demonstrating All Supplementary Figures 1-6 and Supplementary Table 1
View article: Supplementary Table S1 from GnRH-R–Targeted Lytic Peptide Sensitizes <i>BRCA</i> Wild-type Ovarian Cancer to PARP Inhibition
Supplementary Table S1 from GnRH-R–Targeted Lytic Peptide Sensitizes <i>BRCA</i> Wild-type Ovarian Cancer to PARP Inhibition Open
Supplementary Table S1. The IC50s of EP-100 against ovarian cancer cells after 4-, 24-, and 72-h treatment.
View article: Supplementary Materials from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4
Supplementary Materials from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4 Open
File contains synthesis of CN210, sequences for siRNAs, supplementary tables 1 to 3, supplementary figures 1 through 8 and figure legends.
View article: Supplementary Materials from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4
Supplementary Materials from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4 Open
File contains synthesis of CN210, sequences for siRNAs, supplementary tables 1 to 3, supplementary figures 1 through 8 and figure legends.
View article: Supplementary Table 5 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4
Supplementary Table 5 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4 Open
Raw RPPA data for OVCAR 5.
View article: Supplementary materials and Supplementary Figures 1-9 from GnRH-R–Targeted Lytic Peptide Sensitizes <i>BRCA</i> Wild-type Ovarian Cancer to PARP Inhibition
Supplementary materials and Supplementary Figures 1-9 from GnRH-R–Targeted Lytic Peptide Sensitizes <i>BRCA</i> Wild-type Ovarian Cancer to PARP Inhibition Open
Supplementary Materials. Chemical structure and amino acid sequence of EP-100. Supplementary Figure S1. Expression and localization of GnRH-R in ovarian cancer cells. Supplementary Figure S2. The effects of GnRH-R loss on the cytotoxicity …
View article: Data from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4
Data from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4 Open
Systematic approaches for accurate repurposing of targeted therapies are needed. We developed and aimed to biologically validate our therapy predicting tool (TPT) for the repurposing of targeted therapies for specific tumor types by testin…
View article: Supplementary materials and Supplementary Figures 1-9 from GnRH-R–Targeted Lytic Peptide Sensitizes <i>BRCA</i> Wild-type Ovarian Cancer to PARP Inhibition
Supplementary materials and Supplementary Figures 1-9 from GnRH-R–Targeted Lytic Peptide Sensitizes <i>BRCA</i> Wild-type Ovarian Cancer to PARP Inhibition Open
Supplementary Materials. Chemical structure and amino acid sequence of EP-100. Supplementary Figure S1. Expression and localization of GnRH-R in ovarian cancer cells. Supplementary Figure S2. The effects of GnRH-R loss on the cytotoxicity …
View article: Data from Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models
Data from Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models Open
CRM1 inhibitors have demonstrated antitumor effects in ovarian and other cancers; however, rational combinations are largely unexplored. We performed a high-throughput drug library screen to identify drugs that might combine well with seli…
View article: Supplementary Table S2 from GnRH-R–Targeted Lytic Peptide Sensitizes <i>BRCA</i> Wild-type Ovarian Cancer to PARP Inhibition
Supplementary Table S2 from GnRH-R–Targeted Lytic Peptide Sensitizes <i>BRCA</i> Wild-type Ovarian Cancer to PARP Inhibition Open
Supplementary Table S2. The IC50s of EP-100 against shRNA transfected ovarian cancer cells
View article: Supplementary Table 4 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4
Supplementary Table 4 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4 Open
Raw RPPA data for OVCAR 4.
View article: Supplementary Table S2 from GnRH-R–Targeted Lytic Peptide Sensitizes <i>BRCA</i> Wild-type Ovarian Cancer to PARP Inhibition
Supplementary Table S2 from GnRH-R–Targeted Lytic Peptide Sensitizes <i>BRCA</i> Wild-type Ovarian Cancer to PARP Inhibition Open
Supplementary Table S2. The IC50s of EP-100 against shRNA transfected ovarian cancer cells
View article: Data from GnRH-R–Targeted Lytic Peptide Sensitizes <i>BRCA</i> Wild-type Ovarian Cancer to PARP Inhibition
Data from GnRH-R–Targeted Lytic Peptide Sensitizes <i>BRCA</i> Wild-type Ovarian Cancer to PARP Inhibition Open
EP-100 is a synthetic lytic peptide that specifically targets the gonadotropin-releasing hormone receptor on cancer cells. To extend the utility of EP-100, we aimed to identify effective combination therapies with EP-100 for ovarian cancer…
View article: Supplementary Table S1 from GnRH-R–Targeted Lytic Peptide Sensitizes <i>BRCA</i> Wild-type Ovarian Cancer to PARP Inhibition
Supplementary Table S1 from GnRH-R–Targeted Lytic Peptide Sensitizes <i>BRCA</i> Wild-type Ovarian Cancer to PARP Inhibition Open
Supplementary Table S1. The IC50s of EP-100 against ovarian cancer cells after 4-, 24-, and 72-h treatment.
View article: Supplementary data from Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer
Supplementary data from Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer Open
Supplementary Figure 1 Functional genomic analysis of HeyA8 and SKOV3ip ovarian cancer cells 4 h after exposure to norepinephrine and compared to control cells. Supplementary Figure 2 A, Western blot analysis of ADRB1, ADRB2, ADRB3, and DU…
View article: TableS1 from Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression
TableS1 from Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression Open
Table S1
View article: Supplementary Figure 3 from Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47)
Supplementary Figure 3 from Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47) Open
PDF file - 126K, Detailed data are shown for selected proteins assayed by RPPA.
View article: Supplementary Spread Sheet 1 from Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling
Supplementary Spread Sheet 1 from Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling Open
Supplementary Spread Sheet 1
View article: Supplementary Figure 2 from Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47)
Supplementary Figure 2 from Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47) Open
PDF file - 208K, Blood cell counts for all patients on study, except lymphocytes.
View article: Supplementary Movie 2 from Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction
Supplementary Movie 2 from Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction Open
CARS imaging of ex vivo ovarian cancer samples
View article: Data from Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47)
Data from Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47) Open
Purpose: A CTEP-sponsored phase II trial was conducted to evaluate safety and clinical activity of combination therapy with CCI-779 (temsirolimus) and bevacizumab in patients with advanced melanoma.Experimental Design: Patients with unrese…
View article: Figures S1-S6, Table S1-S3 from Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction
Figures S1-S6, Table S1-S3 from Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction Open
Fig. S1. Sustained adrenergic signaling increases nerve counts in tumors. Fig. S2. Characterization of tumoral innervation. Fig. S3. NE induces BDNF expression. Fig. S4. NE-induced BDNF expression is mediated by ADRB3/Epac/Jnk. Fig. S5. BD…
View article: Supplementary Figure S1. Lymphocyte counts from Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47)
Supplementary Figure S1. Lymphocyte counts from Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47) Open
Lymphocyte counts for all patients on study - detail